Moreover, treatment with relatlimab, a novel anti-LAG-3 blocking monoclonal antibody currently under clinical trial for different solid and hematological malignancies including CLL, restored, at least in part, NK and T cell-mediated anti-tumor responses. Here, LAG3 is linked to B-cell chronic lymphocytic leukemia.